Abstract: The present invention relates to antibodies, antibody fragments, and related molecules that specifically bind to DR3 receptors. Such antibodies have uses, for example, in the prevention, detection, diagnosis, treatment or amelioration of a disease or disorder, especially inflammatory and autoimmune diseases and other immune system disorders, such as Crohn's disease, colitis, Inflammatory Bowel Disease, arthritis, asthma, Multiple Sclerosis, atherosclerosis, and allergic disorders. The invention also relates to nucleic acid molecules encoding anti-DR3 receptor antibodies, vectors and host cells containing these nucleic acids, and methods for producing the same.
Type:
Application
Filed:
August 24, 2011
Publication date:
January 19, 2012
Applicants:
Xencor, Inc., Human Genome Sciences, Inc.
Inventors:
Thi-Sau Migone, Chih-Hung Lo, Luke Oh, Heather Wasserman, Madhav Devalaraja, Matthew J. Bernett
Abstract: An antibody that targets CD30, wherein the antibody comprises at least one modification relative to a parent antibody and the antibody binds with altered affinity to an Fc?R or alters effector function as compared to the parent antibody. Also disclosed are methods of using the anti-CD30 antibody.
Type:
Application
Filed:
June 17, 2011
Publication date:
January 19, 2012
Applicant:
Xencor, Inc.
Inventors:
Gregory Alan Lazar, John R. Desjarlais, Philip W. Hammond, David F. Carmichael, Bao-Iu Chen, Seung Y. Chu, Sher Bahadur Karki, Lori Kunkel
Abstract: The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants.
Type:
Grant
Filed:
October 31, 2007
Date of Patent:
January 10, 2012
Assignee:
Xencor, Inc.
Inventors:
Gregory Alan Lazar, Arthur J. Chirino, Wei Dang, John R. Desjarlais, Stephen K. Doberstein, Robert J. Hayes, Sher Bahadur Karki, Omid Vafa
Abstract: The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants.
Type:
Grant
Filed:
July 7, 2006
Date of Patent:
January 10, 2012
Assignee:
Xencor, Inc.
Inventors:
Gregory Alan Lazar, Arthur J. Chirino, Wei Dang, John R. Desjarlais, Stephen Kohl Doberstein, Robert J. Hayes, Sher Bahadur Karki, Omid Vafa
Abstract: The present application relates to a variant Fc region comprising the double mutation 428L/434S that increases serum half-life and the numbering is according to the EU index.
Type:
Grant
Filed:
January 18, 2011
Date of Patent:
January 3, 2012
Assignee:
Xencor, Inc.
Inventors:
Aaron Keith Chamberlain, Bassil I. Dahiyat, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar
Abstract: The present invention relates to optimized CD20 antibodies having Fc variants, methods for their generation, and method for their application, such as methods of enhancing macrophage activation, particularly for therapeutic purposes.
Type:
Grant
Filed:
June 30, 2005
Date of Patent:
December 27, 2011
Assignee:
Xencor, Inc.
Inventors:
Bassil I. Dahiyat, Gregory Alan Lazar, Omid Vafa
Abstract: The present invention relates to immunoglobulins that bind Fc?RIIb+ cells and coengage the antigen on the cell's surface and an Fc?RIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.
Type:
Grant
Filed:
May 30, 2008
Date of Patent:
November 22, 2011
Assignee:
Xencor, Inc.
Inventors:
Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Gregory L. Moore, Igor Vostiar
Abstract: The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants.
Type:
Grant
Filed:
October 31, 2007
Date of Patent:
October 18, 2011
Assignee:
Xencor, Inc.
Inventors:
Gregory Alan Lazar, Arthur J. Chirino, Wei Dang, John R. Desjarlais, Stephen K. Doberstein, Robert J. Hayes, Sher Bahadur Karki, Omid Vafa
Abstract: The present invention relates to Fc variants with optimized properties, methods for their generation, Fc polypeptides comprising Fc variants with optimized properties, and methods for using Fc variants with optimized properties.
Type:
Application
Filed:
May 6, 2011
Publication date:
October 13, 2011
Applicant:
Xencor, Inc.
Inventors:
Gregory Alan Lazar, Wei Dang, John R. Desjarlais, Sher Bahadur Karki
Abstract: The present invention relates to novel methods for generating variant proteins with increased host string content, and proteins that are engineered using these methods.
Type:
Application
Filed:
March 21, 2011
Publication date:
September 29, 2011
Applicant:
Xencor, Inc.
Inventors:
Gregory Alan Lazar, John R. Desjarlais, Philip W. Hammond
Abstract: The present invention relates to novel Fc variants that comprise at least one novel amino acid residue which may provide for enhanced effector function. More specifically, this invention provides Fc variants that have modified binding affinity to one or more Fc receptor or ligand (e.g., Fc gamma R, C1q). Additionally, the Fc variants have altered complement dependent cytotoxicity (CDC) activity and/or antibody-dependent cell-mediated cytotoxicity (ADCC). The invention further provides methods and protocols for the application of said Fc variants, particularly for therapeutic purposes.
Type:
Application
Filed:
January 19, 2011
Publication date:
September 29, 2011
Applicant:
XENCOR, INC.
Inventors:
Gregory A. Lazar, Sher Bahadur Karki, Gregory L. Moore
Abstract: An antibody that targets CD30, wherein the antibody comprises at least one modification relative to a parent antibody and the antibody binds with altered affinity to an FcgR or alters effector function as compared to the parent antibody. Also disclosed are methods of using the anti-CD30 antibody.
Type:
Grant
Filed:
October 6, 2006
Date of Patent:
July 5, 2011
Assignee:
Xencor, Inc.
Inventors:
Gregory Alan Lazar, John R. Desjarlais, Philip W. Hammond, David F. Carmichael, Bao-lu Chen, Seung Y. Chu, Sher Bahadur Karki, Lori Kunkel
Abstract: The present application relates to a variant Fc region comprising the double mutation 428L/434S that increases serum half-life and the numbering is according to the EU index.
Type:
Application
Filed:
January 18, 2011
Publication date:
May 12, 2011
Applicant:
Xencor, Inc.
Inventors:
Aaron Keith Chamberlain, Bassil I. Dahiyat, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar
Abstract: The present invention relates to novel methods for generating variant proteins with increased host string content, and proteins that are engineered using these methods.
Type:
Grant
Filed:
October 31, 2007
Date of Patent:
April 19, 2011
Assignee:
Xencor, Inc.
Inventors:
Gregory Alan Lazar, John R. Desjarlais, Philip W. Hammond
Abstract: The present invention relates to antibody variants outside the Fc region that alter binding affinity to one or more effector ligands, methods for their generation, and their therapeutic application.
Abstract: Immunoglobulin compositions that simultaneously co-engage antigens, where one of the antigens is bound bivalently and the other antigen is bound monovalently. The novel immunoglobulins described preferably utilize heterodimeric Fc regions.
Abstract: The present invention describes humanized antibodies that target CD40, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an Fc?R or alters effector function as compared to the parent antibody. Also disclosed are methods of using the antibodies of the invention.
Type:
Application
Filed:
January 21, 2009
Publication date:
February 3, 2011
Applicant:
Xencor ,Inc.
Inventors:
Matthew J. Bernett, Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Erik Weiking Pong, Eugene Alexande Zhukovsky
Abstract: The present invention relates to Fc variants having decreased affinity for Fc?RIIb, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.
Type:
Application
Filed:
October 1, 2010
Publication date:
January 27, 2011
Applicant:
Xencor, Inc.
Inventors:
Gregory Alan Lazar, Wei Dang, John R. Desjarlais, Sher Bahadur Karki, Omid Vafa, Robert Hayes, Jost Vielmetter